Icagen, based in Research Triangle Park, N.C., focuses on the discovery, development and commercialization of orally-administered, small-molecule drugs that modulate ion channel targets.
Pfizer previously owned 11 percent of Icagen and had invested about $56 million in the company.
Related Articles on Pfizer:
Pfizer Reports “Potentially Improper Payments” Made Outside U.S.
Global Pain Medication Sales Rise 8.9% Since 2005
Study: Lyrica Pain Drug From Pfizer Effective for Spinal Pain
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
